Clinical Trial Update: Switch Study of Existing Atypical Antipsychotics to Bifeprunox [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 switch study evaluating transitioning from existing atypical antipsychotics to bifeprunox for schizophrenia and sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Schizophrenia and Schizoaffective Disorder | Phase 3 | Status: COMPLETED